Major Sponsors of Spain's Largest Cancer Research Center Postpone Funding
In a significant development that could impact the landscape of cancer research in Spain, the major sponsors of the country's largest cancer research center have announced a postponement of their funding commitments. This decision has raised concerns among the scientific community and patients who rely on the advancements made by this esteemed institution.
Background and Impact
The cancer research center in question is a pivotal hub for oncology research, attracting top talent and conducting groundbreaking studies. The center, based in Barcelona, has been at the forefront of innovative treatments and therapies, including the recent presentation of the Phase III ADELA study at the San Antonio Breast Cancer Symposium 2024. This study, a collaboration between the Menarini Group, MEDSIR, and other international partners, focuses on a new therapeutic strategy for advanced ER+/HER2- breast cancer with ESR1 mutations[1].
Read more ->